[gnso-gac-closed-generics] Facilitated Dialogue on Closed Generics: Welcome and Preliminary Administrative Information

[John McElwaine]

Mary,

Other than a few scheduled GNSO council meetings/obligations and U.S. holidays, that I am sure you all are aware of, my January is open.

John

From: gnso-gac-closed-generics <gnso-gac-closed-generics-bounces at icann.org> On Behalf Of Mary Wong
Sent: Thursday, October 13, 2022 5:25 PM
To: gnso-gac-closed-generics at icann.org
Subject: [gnso-gac-closed-generics] Facilitated Dialogue on Closed Generics: Welcome and Preliminary Administrative Information

◄External Email► - From: gnso-gac-closed-generics-bounces at icann.org<mailto:gnso-gac-closed-generics-bounces at icann.org>

Hello everyone,

Thank you all again for agreeing to participate in the facilitated dialogue on the topic of Closed Generic gTLDs. The staff team supporting this work are happy to confirm that all participants appointed by the GAC, the GNSO and the ALAC (including the ALAC’s alternate member) have now been subscribed to this mailing list. This list is now active and available for your use.

Information about the Mailing List & Wiki Space:
Please note the email address for this list is gnso-gac-closed-generics at icann.org<mailto:gnso-gac-closed-generics at icann.org>. We will use this space to communicate information about scheduling, logistics and other administrative details, as well as to coordinate the asynchronous “pre-work” discussed during the Meet-and-Greet session at ICANN75. This work and the on-list interactions are integral to and an extension of the facilitated dialogue itself, so this list and postings to it will be closed to observers while the work is underway. For accountability and transparency purposes, however, the list will be archived once the dialogue has concluded.

In addition to this mailing list, staff has created a wiki space for the dialogue, which can be found at https://community.icann.org/x/6gTVD<https://urldefense.proofpoint.com/v2/url?u=https-3A__community.icann.org_x_6gTVD&d=DwMGaQ&c=qmi9WrYRGQEDDOxOwKrAjW7mWovpzN_EKyRbeK_zbP0&r=Kepk-9GEB6JgOj0vUGl8c0hdrRM7FW-8Is-VAQU1VAm5U0rBXiZs3BfB3GfKU2uR&m=UjySy3GP2RauvJkya3nfGj8_uZfjzNKF4yay5VfltYdW_vPubqSiO12ef7UCthF-&s=TAZkbjN1k_kpUqPigxZoT9UMfcXCtvIBqubEkb0yhHE&e=>. As work progresses, we will post agreed publicly-accessible documents and relevant information to ensure that the work is documented appropriately, including agreed outcomes (if any) following the conclusion of the dialogue.

Location & Dates for an In-Person/Hybrid Dialogue:
As discussed during the Meet-and-Greet session at ICANN75, the relatively short timeline available to plan an in-person/hybrid meeting means that we will need to hold this meeting at an ICANN office. Taking into consideration the location of all participants and available office space, we propose to hold the meeting in Washington, DC, and as discussed at ICANN75, over two days in January 2023.

We recognize that you all have many commitments and very busy schedules and we wish therefore to ensure that planning can proceed as collaboratively and smoothly as possible, To enable us to start the internal processes necessary for the meeting and to allow you to plan your schedules as much in advance as possible, we ask that you each respond to this email with your January 2023 availability. With that information in hand, we hope that we can finalize the dates and other important details quickly.

Thank you for your attention and input. Please look out for additional follow-up emails from staff that will touch on the participation commitments we discussed briefly at ICANN75 as well as distribution of the Problem Statement and associated briefing paper.

Best regards,
Mary (on behalf of the staff team supporting the facilitated dialogue)

Confidentiality Notice
This message is intended exclusively for the individual or entity to which it is addressed. This communication may contain information that is proprietary, privileged, confidential or otherwise legally exempt from disclosure. If you are not the named addressee, you are not authorized to read, print, retain, copy or disseminate this message or any part of it. If you have received this message in error, please notify the sender immediately either by phone (800-237-2000) or reply to this e-mail and delete all copies of this message.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20221017/1cfc5531/attachment.html>